Related Experiment Videos
Angiogenesis: a therapeutic target in arthritis
1Academic Rheumatology, University of Nottingham Clinical Sciences Building, City Hospital, UK. David.Walsh@nottingham.ac.uk
Current Opinion in Investigational Drugs (London, England : 2000)
|March 15, 2002
Summary
Inhibiting pathological blood vessel growth (angiogenesis) shows promise for treating arthritis by reducing joint inflammation and damage. Further clinical studies are needed to confirm the efficacy and safety of these anti-angiogenic therapies in humans.
Area of Science:
- Rheumatology and Oncology
- Vascular Biology and Pharmacology
Background:
- Neovascularization (new blood vessel formation) is crucial for solid tumor growth and also plays a significant role in the pathology of arthritis, specifically in synovitis and bone remodeling.
- Understanding the molecular mechanisms of pathological angiogenesis in arthritis is essential for developing targeted therapies.
- Preclinical studies in animal models of inflammatory arthritis suggest that inhibiting angiogenesis can reduce inflammation and joint damage.
Purpose of the Study:
- To evaluate the potential of pharmacological strategies targeting angiogenesis as a therapeutic approach for inflammatory arthritis.
- To assess the clinical relevance of preclinical findings on angiogenesis inhibitors in the context of rheumatoid arthritis.
- To identify the need for further controlled studies in humans to validate the efficacy and safety of anti-angiogenic agents in treating articular angiogenesis.
Main Methods:
- Review of pharmacological strategies currently in clinical trials for inhibiting neovascularization.
- Analysis of preclinical data from animal models of inflammatory arthritis.
- Evaluation of existing clinical data regarding the efficacy of angiogenesis inhibitors in rheumatoid arthritis.
Main Results:
- Preclinical studies support the hypothesis that inhibiting neovascularization can decrease inflammation and joint damage in arthritis models.
- Clinical data suggest that animal models may predict the efficacy of these inhibitors in rheumatoid arthritis.
- Controlled studies specifically evaluating anti-angiogenic agents in human arthritis are currently limited.
Conclusions:
- Pharmacological inhibition of articular angiogenesis holds potential for ameliorating inflammation and joint damage in arthritis.
- Further clinical research is necessary to confirm the effectiveness of these agents in humans.
- Potential toxicities associated with angiogenesis inhibitors may be managed through strategic application or by targeting disease-specific molecular pathways.